DxTerity Buys Cancer Dx Rights from SourceMDx

DxTerity plans to make the gene expression assays functional with its Non-Enzymatic Amplification Technology platform.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories